← All trials
NCT02888756
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 4, 2017
- Primary completion
- Jun 1, 2017
- Completion date
- Nov 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Erasmus University RotterdamLead sponsor
- IrsiCaixaCollaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- University of BarcelonaCollaborator
- eTheRNACollaborator
- CR2OCollaborator
- Synapse bvCollaborator
- AsphalionCollaborator
- Free University of BrusselsCollaborator
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamSponsor investigator
- Badalona Hospital Germans Trias i PujolCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.